What quality control tests are required for radiopharmaceuticals?
Radiopharmaceutical quality control ensures that a preparation is safe, chemically correct, and suitable for clinical use before administration. QC testing typically assesses radionuclidic purity, radiochemical purity, chemical purity, pH, sterility, and apyrogenicity.
Radiopharmaceutical quality control verifies radionuclide identity, correct chemical form, and absence of contaminants to ensure safe and accurate imaging.
In routine nuclear medicine practice, the most frequently performed tests are radionuclidic purity (e.g. molybdenum breakthrough), radiochemical purity (e.g. thin-layer chromatography), and checks for aluminium contamination in Tc-99m preparations.
Radiopharmaceutical QC ensures correct biodistribution, accurate imaging, and patient safety.
Understanding the physics
Radiopharmaceutical preparation combines radioactive decay physics with chemical labelling processes. Errors at either level can compromise imaging.
Radionuclidic purity confirms that the radioactive isotope present is the intended one. For example, Tc-99m eluate must be tested for molybdenum-99 breakthrough, as Mo-99 contamination increases radiation dose and represents a failure of generator separation.
Radiochemical purity ensures that the radionuclide is in the correct chemical form. For Tc-99m kits, incomplete labelling may leave free pertechnetate or hydrolysed technetium. These species have different biodistribution patterns and may accumulate in unintended tissues. Thin-layer chromatography is commonly used to quantify the fraction of activity in the desired form.
Chemical purity includes testing for non-radioactive contaminants, such as aluminium ions leached from generator columns. Aluminium contamination may interfere with labelling efficiency and alter biodistribution.
Additional quality parameters include pH verification and visual inspection for particulate matter. Sterility and apyrogenicity testing are critical but are often validated at the manufacturing stage for kit preparations.
Because nuclear medicine imaging is highly sensitive to tracer distribution, even small chemical impurities can significantly affect image interpretation.
Where this matters clinically
Poor radiopharmaceutical quality control can lead to:
Unexpected biodistribution
False-positive or false-negative findings
Increased radiation dose
Failed quantitative imaging
Routine QC ensures consistent tracer performance and protects both diagnostic accuracy and patient safety.